文献速递瓣膜外科

二尖瓣修复术后使用维生素K拮抗剂的中风与大出血风险

Risk of Stroke and Major Bleeding With Vitamin K Antagonist Use After Mitral Valve Repair.
PubMed 文献 · Ann Thorac Surg · 2022-10-09

该观察性研究利用全国行政索赔数据库纳入2004至2016年行二尖瓣修复术且无围术期心房颤动的患者,比较出院时使用与不使用维生素K拮抗剂(VKA)的结局。结果显示VKA组180天栓塞性卒中累积发生率与无VKA组无显著差异,但任何原因大出血事件风险显著升高,出院后30天行心包穿刺/心包开窗的需求也增加。

要点

  • 二尖瓣修复术后使用VKA未降低180天栓塞性卒中风险(HR 1.35,P = .38)。
  • VKA组180天任何原因大出血风险显著高于无VKA组(HR 2.09,P < .001)。
  • VKA组出院后30天需心包穿刺/心包开窗的风险增加(HR 3.88,P = .025)。

核心结论

  • 本研究提示二尖瓣修复术后使用VKA不降低脑栓塞事件风险,但与大出血事件风险增加相关。

研究设计与样本

  • 观察性研究,使用全国行政索赔数据库,纳入2004至2016年行二尖瓣修复术且无围术期心房颤动的患者,排除术前心房颤动及使用抗凝药者。
  • 出院时使用VKA者754例,未使用VKA者1462例,采用逆概率加权Cox比例风险模型分析。

主要发现

  • 180天栓塞性卒中累积发生率:VKA组2.21% vs 无VKA组1.50%(HR 1.35,P = .38),无显著差异。
  • 180天任何原因大出血事件:VKA组8.58% vs 无VKA组4.21%(HR 2.09,P < .001),VKA组风险显著增加。
  • 出院后30天需心包穿刺/心包开窗:VKA组1.13% vs 无VKA组0.37%(HR 3.88,P = .025),VKA组需求增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines are discordant on the use of a vitamin K antagonist (VKA) after mitral valve repair (MVr) to reduce the risk of cerebral embolic events. We performed an observational study among patients who underwent a MVr, without perioperative atrial fibrillation, to determine the risk of cerebral ischemic and major bleeding events with or without VKA. METHODS: From 2004 to 2016, we included patients who underwent MVr, using a national administrative claims database. Those with preoperative atrial fibrillation and anticoagulant use were excluded. Patients were stratified based on the presence of a VKA. Inverse probability weighting with a Cox proportional hazard model was used. RESULTS: After MVr, 754 patients were discharged on VKA and 1462 on no-VKA. We found no difference in the cumulative incidence for embolic stroke at 180 days (VKA: 2.21% vs no-VKA: 1.50%; hazard ratio, 1.35; P = .38). However, VKA patients had a significantly increased risk for any-cause major bleeding events at 180 days (VKA: 8.58% vs no-VKA: 4.21%; hazard ratio, 2.09; P < .001). VKA patients also had increased need for a pericardiocentesis/pericardial window at 30 days after discharge (VKA: 1.13% vs no-VKA: 0.37%; hazard ratio, 3.88; P = .025). CONCLUSIONS: Our study suggests that VKA after MVr does not reduce the risk of cerebral embolic events but is associated with an increased risk of major bleeding events.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Brown CR, Sperry AE, Cohen WG, et al. Risk of Stroke and Major Bleeding With Vitamin K Antagonist Use After Mitral Valve Repair. Ann Thorac Surg. 2022. PMID: 36223805. doi:10.1016/j.athoracsur.2022.09.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。